We performed a multicentric analysis aiming to validate recently proposed sex‐specific cutoff values using a homogeneous cohort of newly diagnosed MGMT promoter methylated glioblastoma patients; we included a balanced control cohort for comparison. The gene discussed is MGMT; the disease is glioblastoma.